Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Technical Presentation (September 2018)
12 slides from Nemaura Medical's technical presentation, Sep 12, 2018
Slide 1: Better Diagnostics for Life – Interim Clinical Presentation sugarBEAT
NASDAQ: NMRD Better Diagnostics for Life Interim Clinical Presentation sugarBEAT® 12th September 2018
Slide 2: A Prospective Single Centre Evaluation of the Accuracy and Safety of sugarBEAT
A Prospective Single Centre Evaluation of the Accuracy and safety of the sugarBEAT® Non-invasive Continuous Glucose Monitor (CGM) System: An interim Evaluation Dr T Rahman, MBBS, PhD Clinical research Manager, Nemaura Medical Inc., 2
Slide 3: Study Objective
Study Objective A EU based study to determine the safety and accuracy of the sugarBEAT® CGM to support FDA submission 3
Slide 4: Study Design
Study Design ❖Prospective single arm, single centre study ❖Accuracy and safety assessed over 7 consecutive wear days, consisting of 3 non-consecutive in-clinic visits, and 4 home wear days. ❖Venous blood samples used as reference for in-clinic portion of study using Architect c8000 ❖Abbott Freestyle
Slide 5: Study Methods
Study Methods ❖>25 subjects enrolled for screening at each of 3 stages ❖25 subjects selected after screening in each stage, with approximately equal split between Type 1 and Type 2 ❖No subjects lost due to drop out ❖All 25 subjects completed 2 days home study and 3 days in- clinic study ❖12 subjects
Slide 6: Baseline Characteristics
Baseline Characteristics Variable Age - Range 27-67 years Age - Mean 52.8 years Age - Median 54.5 years Type 1 (n) 12 Type 2 (n) 13 6
Slide 7: Accuracy vs Glucose Range – 1-point Calibration
Accuracy vs Glucose Range In-clinic portion of study 1-point calibration Glucose Number of Within Within Within Within Within Outside ±40% range paired ±10% or ±10 mg/dl ±15% or ±15 mg/dl ±20% or ±20 mg/dl ±30% or ±30 mg/dl ±40% or ±40 mg/dl or ±40 mg/dl (mg/dl) points (MARD) (MARD) (MARD) (MARD) (M
Slide 8: Accuracy vs Glucose Range – 2-point Calibration
Accuracy vs Glucose Range In-clinic portion of study 2-point Calibration Glucose Number of Within Within Within Within Within Outside ±40% range paired ±10% or ±10 mg/dl ±15% or ±15 mg/dl ±20% or ±20 mg/dl ±30% or ±30 mg/dl ±40% or ±40 mg/dl or ±40 mg/dl (mg/dl) points % (MARD) % (MARD) % (MARD) % (
Slide 9: Interim Comparative MARD for In-Clinic phase as Primary Accuracy Metric
Interim Comparative MARD for In-Clinic phase as Primary Accuracy Metric Dexcom G5* no. of Overall MARD 9.00 calibrations (20%/20mg/dL) not known % Data 94.00 1-point Overall MARD sugarBEAT calibraiton (20%/20mg/dL) 8.77 % Data 62.61 2-point Overall MARD calibraiton (20%/20mg/dL) 7.97 % Data 74.00 1-
Slide 10: Interim Comparative MARD for home-study phase as Primary Accuracy Metric
Interim Comparative MARD for home-study phase as Primary Accuracy Metric Note 1: Senseonics, Dexcom G5 and sugarBEAT = 2 point finger prick calibration *http://www.diabetesincontrol.com/accuracy-comparison-of-the-dexcom-g5-abbott-freestyle-libre-pro-and- senseonics-eversense/ 10
Slide 11: Safety Evaluation
Safety Evaluation Previous studies: >100 Patient days wear time – No major adverse events or skin irritation reported. >525 Patient days wear time – No major adverse events or skin irritation reported. Current study: >250 Patient days to date with no major adverse events or skin irritation reported.
Slide 12: Conclusion
Conclusion The interim analysis indicates the 3 day in-clinic portion of the study shows accuracy levels, as measured using overall nominal MARD, as comparable to previously reported data and within the targets for the intended indications. 12
Nemaura Medical — Technical Presentation (September 2018) on 6ix